Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013


#177889

65pages

Global Markets Direct

$ 2000

In Stock

 

Global Markets Directs, 'Recurrent Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Recurrent Head And Neck Cancer Squamous Cell Carcinoma.
  • A review of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

 

 

Table of Content

 

 

Table of Contents 2
List of Tables 4
List of Figures 4
 

Introduction 5
Global Markets Direct Report Coverage 5
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Recurrent Head And Neck Cancer Squamous Cell Carcinoma 7
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Products under Development by Companies 13
Companies Involved in Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Development 14
Amgen Inc. 14
Genentech, Inc. 15
Pfizer Inc. 16
Merck KGaA 17
Oncothyreon Inc 18
PCI Biotech AS 19
Ascenta Therapeutics, Inc. 20
VentiRx Pharmaceuticals, Inc. 21
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
dacomitinib - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
(amphinex + bleomycin sulfate) - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
futuximab - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PX-866 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
panitumumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
VTX-2337 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AT-101 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
RG-7597 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
cetuximab biosimilar - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Drug Profile Updates 48
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Discontinued Products 61
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Dormant Products 62
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones 63
Featured News & Press Releases 63
May 15, 2013: Boehringer Ingelheim To Present Five Abstracts For Afatinib At ASCO 2013 63
 

Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65


Number of Products Under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2013 7
Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Late Stage Development, H2 2013 10
Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Amgen Inc., H2 2013 14
Genentech, Inc., H2 2013 15
Pfizer Inc., H2 2013 16
Merck KGaA, H2 2013 17
Oncothyreon Inc, H2 2013 18
PCI Biotech AS, H2 2013 19
Ascenta Therapeutics, Inc., H2 2013 20
VentiRx Pharmaceuticals, Inc., H2 2013 21
Assessment by Monotherapy Products, H2 2013 22
Assessment by Combination Products, H2 2013 23
Assessment by Stage and Route of Administration, H2 2013 25
Assessment by Stage and Molecule Type, H2 2013 27
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Drug Profile Updates 48
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Discontinued Products 61
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Dormant Products 62


Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2013 7
Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Late Stage Products, H2 2013 10
Mid Clinical Stage Products, H2 2013 11
Pre-Clinical Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 22
Assessment by Combination Products, H2 2013 23
Assessment by Route of Administration, H2 2013 24
Assessment by Stage and Route of Administration, H2 2013 25
Assessment by Molecule Type, H2 2013 26
Assessment by Stage and Molecule Type, H2 2013 27